[go: up one dir, main page]

PE20140134A1 - Metodos para mejorar la oxigenacion del tejido en peligro - Google Patents

Metodos para mejorar la oxigenacion del tejido en peligro

Info

Publication number
PE20140134A1
PE20140134A1 PE2013001082A PE2013001082A PE20140134A1 PE 20140134 A1 PE20140134 A1 PE 20140134A1 PE 2013001082 A PE2013001082 A PE 2013001082A PE 2013001082 A PE2013001082 A PE 2013001082A PE 20140134 A1 PE20140134 A1 PE 20140134A1
Authority
PE
Peru
Prior art keywords
c2ho4
c2ho
blood
patient
methods
Prior art date
Application number
PE2013001082A
Other languages
English (en)
Inventor
Martin Emanuele
Original Assignee
Mast Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mast Therapeutics Inc filed Critical Mast Therapeutics Inc
Publication of PE20140134A1 publication Critical patent/PE20140134A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA AUMENTAR LA SEGURIDAD Y LA EFICACIA DE LAS TRANSFUSIONES DE SANGRE QUE COMPRENDE ADMINISTRAR A UN PACIENTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COPOLIMERO DE POLIOXIETILENO/ POLIOXIPROPILENO CUYA FORMULA ES HO(C2H4O)a-(C3H6O)b-(C2H4O)aH, DONDE b ES UN NUMERO ENTERO TAL QUE LA PORCION HIDROFOBA (C3H6O) TIENE UN PESO MOLECULAR DE 950 A 4000 DALTONES, Y a ES UN NUMERO ENTERO TAL QUE LA PORCION HIDROFILA (C2H4O) REPRESENTA DEL 50 AL 90% EN PESO DEL COMPUESTO; EN DONDE DICHA COMPOSICION SE ADMINISTRA AL PACIENTE ANTES, CONCOMITANTE CON O DESPUES DE LA TRANSFUSION DE SANGRE. TAMBIEN SE REFIERE A UN METODO PARA REDUCIR LOS EFECTOS ADVERSOS DE LA TRANSFUSION DE UN PACIENTE CON SANGRE COMPROMETIDA POR LA LESION DE ALMACENAMIENTO
PE2013001082A 2010-11-15 2011-11-15 Metodos para mejorar la oxigenacion del tejido en peligro PE20140134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41351910P 2010-11-15 2010-11-15

Publications (1)

Publication Number Publication Date
PE20140134A1 true PE20140134A1 (es) 2014-02-14

Family

ID=46084364

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001082A PE20140134A1 (es) 2010-11-15 2011-11-15 Metodos para mejorar la oxigenacion del tejido en peligro

Country Status (17)

Country Link
US (2) US20130177524A1 (es)
EP (1) EP2640684A4 (es)
JP (2) JP5823530B2 (es)
KR (2) KR20130097795A (es)
CN (1) CN103328427A (es)
AU (1) AU2011329088B2 (es)
BR (1) BR112013011858A2 (es)
CA (1) CA2817542A1 (es)
CL (1) CL2013001382A1 (es)
EA (1) EA201390720A1 (es)
IL (1) IL226285A0 (es)
MX (1) MX2013005457A (es)
NZ (1) NZ610441A (es)
PE (1) PE20140134A1 (es)
SG (1) SG190695A1 (es)
WO (1) WO2012068079A1 (es)
ZA (1) ZA201303416B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ610441A (en) * 2010-11-15 2016-02-26 Mast Therapeutics Inc Methods for enhancing oxygenation of jeopardized tissue
GB201207543D0 (en) * 2012-05-01 2012-06-13 Haemair Ltd Treatment of transfusion blood
AU2014337190A1 (en) * 2013-10-16 2016-06-02 Liferaft Biosciences, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
CA2954528A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
WO2020122745A1 (en) 2018-12-10 2020-06-18 Arshintseva Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
CN118076227A (zh) * 2021-08-18 2024-05-24 欧姆尼奥克斯股份有限公司 用于器官保存的h-nox蛋白

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
CA2106474C (en) * 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
EP1804813A4 (en) * 2004-09-27 2011-09-07 Vical Inc FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20110212047A1 (en) * 2007-08-10 2011-09-01 Synth Rx, Inc. Polymer Therapy for the Treatment of Chronic Microvascular Diseases
NZ610441A (en) * 2010-11-15 2016-02-26 Mast Therapeutics Inc Methods for enhancing oxygenation of jeopardized tissue

Also Published As

Publication number Publication date
IL226285A0 (en) 2013-07-31
CL2013001382A1 (es) 2013-12-20
EA201390720A1 (ru) 2013-10-30
KR20150124457A (ko) 2015-11-05
CA2817542A1 (en) 2012-05-24
BR112013011858A2 (pt) 2017-03-21
MX2013005457A (es) 2013-10-17
SG190695A1 (en) 2013-07-31
US20150093368A1 (en) 2015-04-02
EP2640684A1 (en) 2013-09-25
KR20130097795A (ko) 2013-09-03
JP5823530B2 (ja) 2015-11-25
CN103328427A (zh) 2013-09-25
JP2016041714A (ja) 2016-03-31
US20130177524A1 (en) 2013-07-11
JP2014506234A (ja) 2014-03-13
NZ610441A (en) 2016-02-26
EP2640684A4 (en) 2014-04-30
AU2011329088B2 (en) 2016-02-25
AU2011329088A1 (en) 2013-06-27
ZA201303416B (en) 2017-03-29
WO2012068079A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
PE20140134A1 (es) Metodos para mejorar la oxigenacion del tejido en peligro
RU2013121788A (ru) Ингибиторы репликации вич
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
UA114351C2 (uk) Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
CO2018000768A2 (es) Administración intravenosa de citrulina durante la cirugía
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
CO6771403A2 (es) Derivado de acilbenceno
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES
SV2013004582A (es) Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias
RU2016101152A (ru) Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств
NI201200196A (es) Agentes terapéuticos 976

Legal Events

Date Code Title Description
FA Abandonment or withdrawal